Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 433

Similar articles for PubMed (Select 11965579)

1.

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.

Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR.

Liver Transpl. 2002 Apr;8(4):350-5.

2.

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, Van Der Werf W, Lauwers G, Liu C, Crawford JM, Davis GL, Nelson DR.

Liver Transpl. 2002 Nov;8(11):1000-6.

3.

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, Cohard M, Reynes M, Chevallier M, Ducerf C, Baulieux J, Geffner M, Albrecht JK, Bismuth H, Trepo C.

Gastroenterology. 2003 Mar;124(3):642-50.

PMID:
12612903
4.

Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial.

Sulkowski MS, Felizarta F, Smith C, Slim J, Berggren R, Goodman R, Ball L, Khalili M, Dieterich DT; Hepatitis Resource Network Clinical Trials Group.

J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):464-72.

PMID:
15021311
5.

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK.

N Engl J Med. 1998 Nov 19;339(21):1485-92.

6.

Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.

Benetti G, Borzio M, Ramella G, Bellati G, Fargion S, Colombo A, Croce G, Iamoletti C, Balzola F, Rizzetto M; GEL (Gruppo Epatologico Lombardo).

Intern Emerg Med. 2006;1(2):113-8.

PMID:
17111783
7.
8.

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.

Rev Invest Clin. 2003 Mar-Apr;55(2):138-42.

PMID:
12827916
9.
10.

First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.

Reiser M, Buggisch P, Grossmann J, Koop K, Wursthorn K, Schmiegel W.

Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1299-304.

PMID:
14624153
11.

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group.

J Hepatol. 2002 May;36(5):672-80.

PMID:
11983451
12.

Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.

Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, Orloff SL, Rosen HR.

Liver Transpl. 2001 Mar;7(3):181-90.

13.

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, García-Valdecasas JC, Navasa M, Rimola A, Rodés J.

J Hepatol. 2003 Sep;39(3):389-96.

PMID:
12927925
14.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.

AIDS. 2004 Jan 2;18(1):75-9.

PMID:
15090832
15.

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.

Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, Esteban R, Guardia J.

J Hepatol. 2005 Jul;43(1):53-9. Epub 2005 Apr 11.

PMID:
15876467
16.
17.

Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients.

Al-Traif I, Handoo FA, Al-Jumah A, Al-Nasser M.

Saudi Med J. 2004 Dec;25(12):1935-8.

PMID:
15711670
19.

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.

González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M; International Pediatric Hepatitis C Therapy Group.

Hepatology. 2005 Nov;42(5):1010-8.

PMID:
16250032
20.

[Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].

Seydi M, Morlat P, Bonnet F, Rambeloarisoa J, Bernard N, Lacoste D, Bonarek M, Trimoulet P, Ramanampamonjy R, Lafon ME, Dramé M, Beylot J.

Rev Med Interne. 2005 Apr;26(4):280-7. French.

PMID:
15820563
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk